Cargando…
The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447629/ https://www.ncbi.nlm.nih.gov/pubmed/32843656 http://dx.doi.org/10.1038/s41392-020-00283-8 |
| _version_ | 1783574341197234176 |
|---|---|
| author | He, Shenghui |
| author_facet | He, Shenghui |
| author_sort | He, Shenghui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7447629 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74476292020-09-02 The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer He, Shenghui Signal Transduct Target Ther Research Highlight Nature Publishing Group UK 2020-08-25 /pmc/articles/PMC7447629/ /pubmed/32843656 http://dx.doi.org/10.1038/s41392-020-00283-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Research Highlight He, Shenghui The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| title | The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| title_full | The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| title_fullStr | The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| title_full_unstemmed | The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| title_short | The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| title_sort | first human trial of crispr-based cell therapy clears safety concerns as new treatment for late-stage lung cancer |
| topic | Research Highlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447629/ https://www.ncbi.nlm.nih.gov/pubmed/32843656 http://dx.doi.org/10.1038/s41392-020-00283-8 |
| work_keys_str_mv | AT heshenghui thefirsthumantrialofcrisprbasedcelltherapyclearssafetyconcernsasnewtreatmentforlatestagelungcancer AT heshenghui firsthumantrialofcrisprbasedcelltherapyclearssafetyconcernsasnewtreatmentforlatestagelungcancer |